Asthma and Allergies: Understanding the Connection

Medically reviewed | Florida Asthma Clinic | Updated May 2026

If you have asthma, there is a strong chance that an allergy is making it worse — or even driving it entirely. Research consistently shows that up to 80 percent of people with asthma have at least one allergic trigger. Understanding why these two conditions are so tightly linked, which allergens are most problematic in Florida, and how to treat both at the same time is the foundation of lasting asthma control.

How Common Is the Asthma-Allergy Link?

Allergic asthma is the most prevalent form of asthma in both children and adults. Studies across multiple populations estimate that between 60 and 80 percent of asthma patients are sensitised to at least one environmental allergen, meaning their immune system has produced specific IgE antibodies against it. In children the proportion is even higher, with some paediatric studies placing the figure above 85 percent.

The connection runs both ways. People with allergic rhinitis — hay fever — are three to six times more likely to develop asthma than those without it. This is why physicians increasingly speak of a "united airway" model: the nasal passages and the lungs share the same mucosal lining and the same inflammatory pathways. When those pathways are chronically activated by allergen exposure, both the upper and lower airways suffer the consequences.

Recognising this link matters practically because treating only the asthma while leaving untreated allergic inflammation in the nose and sinuses typically produces suboptimal control. Full improvement often requires addressing both conditions together.

The Mechanism: From Allergen to Airway Narrowing

The chain of events that connects an allergen exposure to an asthma attack is well understood at the molecular level. On first contact with an allergen — say, a grass pollen grain — the immune system of a genetically susceptible individual mounts a response mediated by immunoglobulin E, or IgE. B cells produce IgE antibodies specific to proteins on that pollen. Those antibodies bind to receptors on the surface of mast cells and basophils throughout the airway lining, effectively arming them.

On subsequent exposure to the same allergen, IgE antibodies on the mast cell surface bind directly to the allergen. This cross-linking triggers mast cell degranulation — the rapid release of preformed mediators including histamine, tryptase and heparin, followed by the synthesis of leukotrienes and prostaglandins. These mediators cause the immediate-phase response: airway smooth muscle contraction, mucus hypersecretion and increased vascular permeability. The result is bronchoconstriction — the sudden tightening and narrowing of the airways responsible for the acute wheeze and breathlessness of an asthma attack.

Several hours later, a late-phase reaction can occur as inflammatory cells — eosinophils, T-helper 2 lymphocytes and additional mast cells — migrate into the airway wall. This late-phase inflammation damages the airway epithelium, thickens the basement membrane, and drives the chronic airway remodelling that makes asthma progressively harder to control if the underlying allergen sensitisation is not addressed.

Florida-Specific Allergens: A Year-Round Challenge

Florida's subtropical climate creates an allergen environment that is distinctly more demanding than in temperate states. Residents who move from northern states are often surprised to find that allergy seasons do not follow the predictable spring-to-fall arc they were accustomed to. Several major allergen categories are worth knowing.

Tree, grass and weed pollen. Oak trees pollinate heavily from late winter through spring, and in Florida this season can begin as early as January. Grass pollen — particularly from Bermuda, bahia and rye grasses — peaks in spring and summer but remains present well into autumn. Ragweed, the most potent weed allergen, pollinates from late summer through the first cold snap, which in South Florida may not arrive until December. The result is a nearly continuous pollen calendar that leaves little recovery time for sensitised patients.

Mold spores. High humidity throughout the year — Florida regularly records relative humidity above 80 percent — supports prolific outdoor and indoor mold growth. Alternaria and Cladosporium are the outdoor molds most commonly linked to asthma attacks. Indoor mold colonises bathrooms, window frames, air conditioning units and any area with water infiltration. Mold spore counts spike after rain and during humid summer months, often correlating directly with emergency department asthma admissions.

Cockroach allergen. Cockroach fecal particles and shed body parts are a major indoor allergen, particularly in apartment buildings and urban housing where warm temperatures and food sources support large infestations. Research has identified cockroach sensitisation as one of the strongest predictors of asthma morbidity in children living in cities. The warm Florida climate extends cockroach activity year-round.

Dust mites. House dust mites thrive in temperatures between 20 and 30 degrees Celsius with humidity above 50 percent — conditions that describe most Florida homes for the majority of the year. Mite allergens concentrate in bedding, upholstered furniture, carpets and soft toys, making the bedroom a critical exposure site.

Allergic vs Non-Allergic Asthma: How to Tell the Difference

Not all asthma is allergic. Non-allergic asthma — sometimes called intrinsic asthma — is triggered by irritants such as cold air, strong odours, air pollution, exercise or respiratory infections rather than by IgE-mediated allergen responses. Distinguishing between the two subtypes has practical consequences because the treatments, while overlapping, are not identical.

Allergic asthma tends to follow a predictable pattern. Symptoms worsen during specific pollen seasons, after entering buildings with pets, or after disturbing dusty environments. It is frequently accompanied by allergic rhinitis, conjunctivitis or eczema. It typically begins in childhood or adolescence, and a family history of allergy is common. Total serum IgE is often elevated, and allergy skin testing or blood testing identifies specific sensitivities.

Non-allergic asthma more commonly develops in adulthood, particularly in women after respiratory infections. It is less likely to be associated with elevated IgE, and allergy tests return negative results. Triggers tend to be non-specific irritants. Eosinophilic non-allergic asthma — characterised by elevated eosinophil counts in blood or sputum — is a recognised subtype that responds to specific biologic therapies even in the absence of IgE sensitisation.

Many patients have features of both types simultaneously, and a thorough specialist evaluation is the only reliable way to determine which mechanisms are at work in an individual patient.

Diagnosis: Testing for Allergic Triggers

Identifying the specific allergens responsible for a patient's symptoms requires objective testing rather than guesswork. Several validated methods are available.

Skin prick testing is the most widely used and cost-effective first-line investigation. Small amounts of standardised allergen extracts are introduced just below the skin surface on the forearm or back. A positive result — a raised, itchy wheal forming within 15 to 20 minutes — indicates IgE-mediated sensitisation to that substance. A skilled allergist can test 20 to 40 allergens in a single visit and has results in hand within half an hour. Antihistamines must be stopped several days beforehand, as they suppress the skin response.

Specific IgE blood tests, commercially available as ImmunoCAP or RAST assays, measure the concentration of allergen-specific IgE antibodies circulating in the blood. They are useful when skin testing is not feasible — for example in patients with severe eczema, those who cannot stop antihistamines, or young children who cannot tolerate the procedure. Results are expressed as numeric values (kU/L), allowing the clinician to gauge the degree of sensitisation.

Patch testing is a separate procedure used to detect delayed-type (Type IV) contact hypersensitivity rather than IgE-mediated allergy. It is relevant primarily for contact dermatitis and is not a routine component of asthma evaluation, though it may be performed when occupational allergens or skin conditions coexist with asthma.

Nasal eosinophil assessment via nasal cytology or lavage can detect eosinophilic airway inflammation in the upper airway, supporting a diagnosis of allergic rhinitis and helping to characterise the type 2 inflammatory phenotype that predicts a good response to certain biologic therapies.

Dual Treatment: Controlling Asthma and Allergies Together

Because allergic inflammation in the nose and lungs share the same underlying mechanisms, the most effective management strategies address both simultaneously. Standard pharmacological building blocks include:

• Inhaled corticosteroids (ICS) — the cornerstone of chronic asthma management. Daily use reduces airway eosinophilia, decreases mucosal swelling and lowers bronchial hyperresponsiveness. Common agents include fluticasone, budesonide and beclomethasone.
• Nasal corticosteroid sprays — fluticasone nasal spray, mometasone or budesonide nasal formulations reduce allergic inflammation in the upper airway. Consistent daily use decreases the nasal drip and postnasal secretions that themselves trigger coughing and lower airway irritation. Multiple studies show that treating allergic rhinitis with nasal corticosteroids independently improves asthma outcomes.
• Antihistamines — oral non-sedating antihistamines such as cetirizine, loratadine and fexofenadine block H1 histamine receptors and reduce sneezing, itching and nasal congestion. While their direct bronchodilator effect is modest, reducing the allergic nasal load lessens the burden on the lower airway.
• Long-acting beta-agonists (LABA) — when ICS alone is insufficient, the addition of a LABA such as salmeterol or formoterol provides sustained bronchodilation. LABAs are always prescribed in combination with an ICS, never as standalone therapy, in asthma patients.
• Leukotriene receptor antagonists — montelukast blocks leukotriene receptors that are activated both by allergen exposure and by mast cell degranulation. It has dual benefit in allergic rhinitis and asthma, making it a practical add-on option for patients with both conditions.

Allergen Immunotherapy: Modifying the Disease

Unlike the medications listed above, which control symptoms without changing the underlying immune response, allergen immunotherapy has the potential to modify the course of allergic disease. It works by exposing the immune system to gradually increasing doses of the allergen until tolerance is achieved — a process called desensitisation.

Subcutaneous immunotherapy (SCIT), commonly known as allergy shots, is the most established form. After an initial build-up phase of weekly injections over several months, patients receive maintenance injections every 3 to 4 weeks. A full treatment course typically spans 3 to 5 years. Evidence from numerous randomised controlled trials demonstrates that SCIT reduces asthma symptoms and medication requirements, decreases airway hyperresponsiveness, and prevents new allergen sensitivities from developing. Importantly, benefits persist for years after the injections are stopped, unlike symptomatic medications that work only while being taken.

Sublingual immunotherapy (SLIT) delivers allergen extracts as drops or dissolvable tablets placed under the tongue, allowing administration at home after the initial supervised doses. SLIT is approved for house dust mite, grass pollen and ragweed in standardised tablet form. It is a particularly useful option for patients unable to commit to the injection schedule or those with needle anxiety. Its efficacy in asthma, while growing, is generally considered slightly less robust than that of SCIT, though convenience improves adherence.

Biologic Medications for Severe Allergic Asthma

For patients with moderate-to-severe allergic asthma that is not adequately controlled despite high-dose ICS plus LABA therapy, biologic medications offer a precision approach that targets specific molecules in the allergic inflammatory cascade.

Omalizumab (Xolair) was the first approved biologic for asthma. It is a monoclonal antibody that binds to free circulating IgE, preventing it from attaching to mast cell and basophil receptors. Without receptor-bound IgE, allergen exposure cannot trigger degranulation. Omalizumab significantly reduces asthma exacerbation rates, emergency visits and oral corticosteroid requirements in patients with confirmed IgE-mediated allergic asthma. It is given by subcutaneous injection every 2 to 4 weeks, with the dose calculated from the patient's body weight and baseline IgE level.

Dupilumab (Dupixent) blocks the shared receptor component for interleukin-4 and interleukin-13 — two cytokines central to the type 2 inflammatory response that underlies both allergic asthma and atopic dermatitis. By interrupting this signalling pathway, dupilumab reduces eosinophilic airway inflammation, improves lung function and cuts exacerbation frequency. It is effective in a broader population than omalizumab because it addresses type 2 inflammation regardless of whether the trigger is strictly IgE-mediated. Dupilumab is self-administered by subcutaneous injection every 2 weeks and is also approved for allergic rhinitis and eczema — a notable advantage for patients managing multiple atopic conditions simultaneously.

Environmental Control Strategies

No medication programme achieves its full potential if the patient returns home to an allergen-saturated environment every night. Reducing allergen load in the home is a cost-effective, evidence-supported component of allergic asthma management.

• HEPA air filtration. High-efficiency particulate air filters capture particles as small as 0.3 microns, removing pollen, mold spores, pet dander and cockroach allergen particles from indoor air. Placing a HEPA purifier in the bedroom — where most allergen exposure occurs during sleep — has demonstrated measurable benefits in asthma control studies.
• Mattress and pillow encasements. Allergen-impermeable covers made from tightly woven microfibre or zippered plastic encase mattresses and pillows, creating a barrier between the sleeper and the dense dust mite population within the bedding. Washing all bedding in hot water (above 55 degrees Celsius) weekly kills mites and removes their allergen-laden fecal particles.
• Dehumidifiers for mold control. Maintaining indoor relative humidity below 50 percent inhibits both dust mite reproduction and mold growth. In Florida's climate, a dehumidifier running continuously in living areas and bedrooms is often necessary, particularly during summer months. Air conditioning units with regular filter cleaning serve a dual function of cooling and humidity reduction.
• Cockroach management. Integrated pest management — sealing cracks and crevices, eliminating food and water sources, using bait stations rather than sprays — reduces cockroach populations more effectively and with less chemical irritant exposure than conventional pesticide applications. Vacuuming with a HEPA-equipped vacuum removes accumulated allergen from floors and upholstery.
• Outdoor pollen avoidance. Keeping windows closed and relying on air conditioning during high pollen periods, checking daily pollen counts before outdoor activity, showering and changing clothes after significant outdoor exposure, and avoiding early morning outdoor exercise during peak pollen release hours can meaningfully reduce total allergen dose in sensitised individuals.

Frequently Asked Questions